摘要
目的探讨血管紧张素Ⅱ(AngⅡ)1型受体拮抗剂(ARB)厄贝沙坦对2型糖尿病(T2DM)大鼠肾小管上皮细胞基质金属蛋白酶-2(MMP-2)/基质金属蛋白酶组织抑制物-2(TIMP-2)和α-平滑肌肌动蛋白(α-SMA)表达关系的影响及其肾脏功能保护的可能机制。方法将实验大鼠随机分成正常对照组(A组)、糖尿病组(B组)、厄贝沙坦治疗组(C组),8周时用免疫组织化学法检测肾脏α-SMA、MMP-2、TIMP-2表达并进行相关分析。结果 (1)与A组比较,B组大鼠肾脏α-SMA、TIMP-2表达明显增强,MMP-2表达减弱(P<0.05);(2)α-SMA蛋白含量与肌酐清除率(Ccr)、MMP-2呈明显的负相关;与TIMP-2蛋白含量之间呈正相关。结论糖尿病肾病(DN)存在肾小管间质纤维化的病理变化,且与肾功能密切相关;MMP-2/TIMP-2与肾小管纤维化密切相关;厄贝沙坦具有延缓肾小管纤维化进展的作用。
Objective To investigate effect of angiotensin II （Ang II ）type 1 receptor block ebesartan on expression of renal MMP-2/TIMP-2 and α-SMA in rats with type 2 diabetes. Methods All rats were divided into control group（group A）, diabetes mellitus group（group B） and treating group（group C）. Type 2 diabetec rats were treated with ebsartan or vehicle respectively. Immunohistochemistry was used to measure expression of MMP2 ,TIMP-2 and α-SMA at 8th week. Results （1） In the group B,expression of α-SMA and TIMP-2 were significant higher than the group A and was lower in MMP-2 expression（P〈0.05）. （2）α- SMA had a significant negative correlation with tubular MMP-2 protein expression and Ccr,and a positive correlation with TIMP-2 expression. Conclusion Tubulointerstitial fibrosis was involved in the pathogenesis of the injury of type 2 diabetic nephropathy. Ebesartan can restra in the process of Tubulointerstitial fibrosis in type 2 diabetic rats.
出处
《重庆医学》
CAS
CSCD
北大核心
2012年第29期3030-3032,F0002,共4页
Chongqing medicine
